📰 Future Milestones News
Future Milestones News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Future Milestones. Real-time updates on events, politics, business and more.
September 15, 2023
In a compelling interview, Shafat Qazi, a prominent data scientist and founder of BQE Software, emphasises the transformative impact of AI and technology on our future. Qazi's journey from Kashmir to Silicon Valley serves as a testament to the global reach of technology innovation. He envisions a world where AI-driven advancements, such as autonomous vehicles, will reshape society. Qazi also discusses the evolution of BQE Software and the potential of tech startups in Kashmir. He dismisses ...
July 30, 2023
4D Molecular Therapeutics, Inc. announced additional positive interim clinical data from the Phase 1 Dose Exploration stage of the 4D-150 Phase 1/2 PRISM clinical trial for patients with wet...
May 4, 2022
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2022 and reiterated...
February 11, 2022
SAN DIEGO, Feb. 11, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter ...
February 11, 2022
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31,...
February 11, 2022
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31,...
January 6, 2022
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product sales...
January 6, 2022
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product sales...
December 21, 2021
- Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe